We are thrilled to attend the 2024 European Society for Medical Oncology (ESMO) Congress, which takes place this September 13-17 in Barcelona, Spain.
The annual ESMO meeting brings together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world to share cutting-edge data, education, and networking opportunities. Learn more about ESMO Congress 24.
We invite you to visit the Quest Diagnostics booth (#637) to learn about ultrasensitive minimal residual disease (MRD) testing using Haystack MRD™ and how the test can revolutionize care for patients who have been diagnosed with solid tumors.
Meet the Haystack MRD team at ESMO Congress 24
Representatives from our team will be on hand to answer any questions you may have and to discuss opportunities to support your research. Visit booth #637 or click here to schedule a meeting with one of our team members.
About Haystack MRD
Next-generation ctDNA detection with exquisite sensitivity and specificity for precise MRD reporting
Haystack MRD is a tumor-informed ctDNA detection test for postsurgical measurement of residual disease in solid tumor settings. The test is powered by sequencing chemistry that significantly reduces noise to detect even the least-abundant ctDNA molecules in blood. This unique ability translates to better minimal residual disease (MRD) detection for greater confidence when making key clinical decisions.
Purpose-built MRD technology developed by pioneers of cancer research
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual, recurrent, and resistant disease. Better sensitivity means the right patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
Backed by the power of Quest
Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless, providing ease and convenience in the testing process for doctors and patients.
Stay connected
Follow us on LinkedIn or X for updates and highlights from the ESMO Congress.
Contact us
For more information or to schedule a meeting with the Haystack MRD team at ESMO Congress 24, contact us here.
We look forward to seeing you in Barcelona!
